Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapsed Adult AML: early-phase trial registry
3 of 3 indexed Relapsed Adult AML trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Relapsed Adult AML: 3 US clinical trials tracked, 3 recruiting.
Relapsed Adult AML is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Pacylex Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition relapsed-adult-aml
OPEN 3 | RECR 100% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Relapsed Adult AML lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapsed Adult AML on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapsed Adult AML is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Massachusetts General Hospital
NCT05237258
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Aptose Biosciences
NCT03850574
Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
Pacylex Pharmaceuticals
NCT06613217
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapsed Adult AML records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapsed Adult AML trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapsed Adult AML page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Relapsed Adult AML trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pacylex Pharmaceuticals sponsors the most Relapsed Adult AML trials on record, review their full trial history before evaluating a specific study. See Pacylex Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsed Adult AML condition card totals 3 registered trials; most-linked intervention Primary Palliative Care; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.